Will Lawn, Xuejun Hao, Anna B Konova, Margaret Haney, Ziva D Cooper, Nicholas Van Dam, Paul Glimcher, Gillinder Bedi
{"title":"在几乎每天使用大麻的人群中,价值信号指导大麻与非药物奖励的选择。","authors":"Will Lawn, Xuejun Hao, Anna B Konova, Margaret Haney, Ziva D Cooper, Nicholas Van Dam, Paul Glimcher, Gillinder Bedi","doi":"10.1007/s00213-025-06746-6","DOIUrl":null,"url":null,"abstract":"<p><strong>Rationale: </strong>Despite the critical role of choice processes in substance use disorders, the neurobehavioral mechanisms guiding human decisions about drugs remain poorly understood.</p><p><strong>Objectives: </strong>We aimed to characterize the neural encoding of subjective value (SV) for cannabis versus non-drug rewards (snacks) in people who use cannabis on a near-daily/daily frequency (PWUCF) and assessed the impact of cannabis and snack stimuli ('cues') on SV encoding.</p><p><strong>Methods: </strong>Twenty-one non-treatment-seeking PWUCF (≥4 days/week; 1 female) participated in an inpatient, crossover experiment with four counterbalanced conditions: 1. neutral cues/cannabis choices; 2. cannabis cues/cannabis choices; 3. neutral cues/snack choices; and 4. snack cues/snack choices. In each condition, participants were exposed to cues before an fMRI scan during which they repeatedly chose between 0-6 cannabis puffs/snacks and a set monetary amount, with randomly-selected choices implemented. The SV signal was operationalized as the neural correlates of the strength of preference for cannabis/snack choices. fMRI data were analyzed for twenty participants.</p><p><strong>Results: </strong>Despite equivalent choice behavior, SV signals for cannabis, but not snacks, were observed in regions known to encode SV for various rewards (ventromedial prefrontal cortex, vmPFC; ventral striatum; dorsal posterior cingulate cortex, dPCC). SV encoding in vmPFC was stronger for cannabis than snacks. In the dPCC, the impact of cues on SV signals was moderated by reward type.</p><p><strong>Conclusions: </strong>PWUCF had expected neural value encoding for cannabis but disrupted non-drug SV encoding, despite equivalent choice behavior. This provides tentative support for theories that highlight dysregulated neural valuation of non-drug rewards as a hallmark of problematic cannabis use.</p>","PeriodicalId":20783,"journal":{"name":"Psychopharmacology","volume":" ","pages":"681-691"},"PeriodicalIF":3.5000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11890362/pdf/","citationCount":"0","resultStr":"{\"title\":\"Value signals guiding choices for cannabis versus non-drug rewards in people who use cannabis near-daily.\",\"authors\":\"Will Lawn, Xuejun Hao, Anna B Konova, Margaret Haney, Ziva D Cooper, Nicholas Van Dam, Paul Glimcher, Gillinder Bedi\",\"doi\":\"10.1007/s00213-025-06746-6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Rationale: </strong>Despite the critical role of choice processes in substance use disorders, the neurobehavioral mechanisms guiding human decisions about drugs remain poorly understood.</p><p><strong>Objectives: </strong>We aimed to characterize the neural encoding of subjective value (SV) for cannabis versus non-drug rewards (snacks) in people who use cannabis on a near-daily/daily frequency (PWUCF) and assessed the impact of cannabis and snack stimuli ('cues') on SV encoding.</p><p><strong>Methods: </strong>Twenty-one non-treatment-seeking PWUCF (≥4 days/week; 1 female) participated in an inpatient, crossover experiment with four counterbalanced conditions: 1. neutral cues/cannabis choices; 2. cannabis cues/cannabis choices; 3. neutral cues/snack choices; and 4. snack cues/snack choices. In each condition, participants were exposed to cues before an fMRI scan during which they repeatedly chose between 0-6 cannabis puffs/snacks and a set monetary amount, with randomly-selected choices implemented. The SV signal was operationalized as the neural correlates of the strength of preference for cannabis/snack choices. fMRI data were analyzed for twenty participants.</p><p><strong>Results: </strong>Despite equivalent choice behavior, SV signals for cannabis, but not snacks, were observed in regions known to encode SV for various rewards (ventromedial prefrontal cortex, vmPFC; ventral striatum; dorsal posterior cingulate cortex, dPCC). SV encoding in vmPFC was stronger for cannabis than snacks. In the dPCC, the impact of cues on SV signals was moderated by reward type.</p><p><strong>Conclusions: </strong>PWUCF had expected neural value encoding for cannabis but disrupted non-drug SV encoding, despite equivalent choice behavior. This provides tentative support for theories that highlight dysregulated neural valuation of non-drug rewards as a hallmark of problematic cannabis use.</p>\",\"PeriodicalId\":20783,\"journal\":{\"name\":\"Psychopharmacology\",\"volume\":\" \",\"pages\":\"681-691\"},\"PeriodicalIF\":3.5000,\"publicationDate\":\"2025-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11890362/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Psychopharmacology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s00213-025-06746-6\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/2/10 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"NEUROSCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Psychopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00213-025-06746-6","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/10 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
Value signals guiding choices for cannabis versus non-drug rewards in people who use cannabis near-daily.
Rationale: Despite the critical role of choice processes in substance use disorders, the neurobehavioral mechanisms guiding human decisions about drugs remain poorly understood.
Objectives: We aimed to characterize the neural encoding of subjective value (SV) for cannabis versus non-drug rewards (snacks) in people who use cannabis on a near-daily/daily frequency (PWUCF) and assessed the impact of cannabis and snack stimuli ('cues') on SV encoding.
Methods: Twenty-one non-treatment-seeking PWUCF (≥4 days/week; 1 female) participated in an inpatient, crossover experiment with four counterbalanced conditions: 1. neutral cues/cannabis choices; 2. cannabis cues/cannabis choices; 3. neutral cues/snack choices; and 4. snack cues/snack choices. In each condition, participants were exposed to cues before an fMRI scan during which they repeatedly chose between 0-6 cannabis puffs/snacks and a set monetary amount, with randomly-selected choices implemented. The SV signal was operationalized as the neural correlates of the strength of preference for cannabis/snack choices. fMRI data were analyzed for twenty participants.
Results: Despite equivalent choice behavior, SV signals for cannabis, but not snacks, were observed in regions known to encode SV for various rewards (ventromedial prefrontal cortex, vmPFC; ventral striatum; dorsal posterior cingulate cortex, dPCC). SV encoding in vmPFC was stronger for cannabis than snacks. In the dPCC, the impact of cues on SV signals was moderated by reward type.
Conclusions: PWUCF had expected neural value encoding for cannabis but disrupted non-drug SV encoding, despite equivalent choice behavior. This provides tentative support for theories that highlight dysregulated neural valuation of non-drug rewards as a hallmark of problematic cannabis use.
期刊介绍:
Official Journal of the European Behavioural Pharmacology Society (EBPS)
Psychopharmacology is an international journal that covers the broad topic of elucidating mechanisms by which drugs affect behavior. The scope of the journal encompasses the following fields:
Human Psychopharmacology: Experimental
This section includes manuscripts describing the effects of drugs on mood, behavior, cognition and physiology in humans. The journal encourages submissions that involve brain imaging, genetics, neuroendocrinology, and developmental topics. Usually manuscripts in this section describe studies conducted under controlled conditions, but occasionally descriptive or observational studies are also considered.
Human Psychopharmacology: Clinical and Translational
This section comprises studies addressing the broad intersection of drugs and psychiatric illness. This includes not only clinical trials and studies of drug usage and metabolism, drug surveillance, and pharmacoepidemiology, but also work utilizing the entire range of clinically relevant methodologies, including neuroimaging, pharmacogenetics, cognitive science, biomarkers, and others. Work directed toward the translation of preclinical to clinical knowledge is especially encouraged. The key feature of submissions to this section is that they involve a focus on clinical aspects.
Preclinical psychopharmacology: Behavioral and Neural
This section considers reports on the effects of compounds with defined chemical structures on any aspect of behavior, in particular when correlated with neurochemical effects, in species other than humans. Manuscripts containing neuroscientific techniques in combination with behavior are welcome. We encourage reports of studies that provide insight into the mechanisms of drug action, at the behavioral and molecular levels.
Preclinical Psychopharmacology: Translational
This section considers manuscripts that enhance the confidence in a central mechanism that could be of therapeutic value for psychiatric or neurological patients, using disease-relevant preclinical models and tests, or that report on preclinical manipulations and challenges that have the potential to be translated to the clinic. Studies aiming at the refinement of preclinical models based upon clinical findings (back-translation) will also be considered. The journal particularly encourages submissions that integrate measures of target tissue exposure, activity on the molecular target and/or modulation of the targeted biochemical pathways.
Preclinical Psychopharmacology: Molecular, Genetic and Epigenetic
This section focuses on the molecular and cellular actions of neuropharmacological agents / drugs, and the identification / validation of drug targets affecting the CNS in health and disease. We particularly encourage studies that provide insight into the mechanisms of drug action at the molecular level. Manuscripts containing evidence for genetic or epigenetic effects on neurochemistry or behavior are welcome.